Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is currently conducting a Phase 3 clinical study titled ‘Golden Gate Study,’ which aims to evaluate the effectiveness of blinatumomab alternating with low-intensity chemotherapy compared to standard of care chemotherapy in older adults with newly diagnosed Philadelphia-negative B-cell precursor acute lymphoblastic leukemia. The study’s primary objectives are to assess event-free survival and overall survival rates, highlighting its significance in potentially improving treatment outcomes for this patient group.
The study tests the intervention of blinatumomab, a continuous intravenous infusion, combined with low-intensity chemotherapy, administered through various methods. This combination is compared against standard chemotherapy regimens to determine its efficacy and safety.
The study is designed as a randomized, parallel intervention model with no masking, focusing on treatment as the primary purpose. This straightforward design ensures clear comparisons between the experimental and standard treatment groups.
Key dates for the study include its start on November 2, 2021, with the most recent update submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
The outcome of this study could significantly impact Amgen’s stock performance, as positive results may enhance investor confidence and market position. It also positions Amgen competitively within the oncology sector, particularly against other companies developing treatments for similar conditions.
The study is ongoing, with further details available on the ClinicalTrials portal.